|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
<b>Objective:</b> Using the gastric cancer cell line SGC7901, we constructed a cell line that overexpressed octamer-binding protein 4 (Oct4) and SRY-box 2 (Sox2) to explore the stem cell oncological and biological characteristics of these cells and to elucidate the mechanisms of Oct4 and Sox2 in cancer.
|
31417271 |
2019 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
<i>NANOG</i> and <i>OCT3/4</i> mRNA expression levels were significantly downregulated while that of <i>SOX2</i> was upregulated in cancer compared to noncancer tissues.
|
29849920 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Cancer stem cell-like cells (CSCLC) are reported to be a minor population in tumors or even in tumor cell lines which also express Oct4.
|
18701476 |
2008 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Cancer Stem Cells (CSCs), which in some cases express markers of pluripotency (e.g., Oct-4), share many of the molecular features of normal stem cells.
|
27730468 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells (CSCs) are responsible for the resistance of osteosarcoma to chemotherapy and OCT4, SOX2 and SSEA4 have been used to identify CSCs in osteosarcoma.
|
28934267 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells were analyzed using the marker Oct-4 to improve an understanding of the proliferative ability of cancer stem cells under various pathological conditions, which may lead to the development of novel cancer therapeutics.
|
29142598 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct-3/4 highly expressed in cancer cells may be a potential target for cancer therapy.
|
18281558 |
2008 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Oct4, a member of the POU-domain transcription factor family, has been implicated in the cancer stem cell (CSC)-like properties of various cancers.
|
22037460 |
2011 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct4 is expressed by CSC-like cells in different types of cancer.
|
22286766 |
2012 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct4 was reported to be one of the most important pluripotency transcription factors in the biology of stem cells including cancer stem cells, and progressed malignant cells.
|
28426762 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
OCT4 is expressed in germ cell tumors but also aberrantly in cancers developing in differentiated tissues.
|
28911263 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma.
|
29901157 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct4 expression cells have self-renewal and differentiation abilities like those of cancer stem cells.
|
31191684 |
2019 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
A similar treatment also modulated numerous microRNAs (miRs) including one regulator of Oct4 as well as miRs involved in oncogenesis and/or malignancy, with only a few estrogen-induced miRs.
|
27959387 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
A strategy to target "cancer stem cells" is to suppress the Oct-4 gene in order to cause the cells to differentiate.
|
17261754 |
2006 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
After the treatment period, the tumor tissues were weighed and harvested for mRNA and protein isolation. qPCR and Western blotting were used to evaluate the expression of cancer stemness markers (epithelial cell adhesion molecule [EpCAM], cluster of differentiation [CD13], CD90, aldehyde dehydrogenase 1 [ALDH1], CD44, and CD45), totipotency factors (sex determining region Y-box 2 [Sox2], Nanog, and octamer-binding transcription factor 4 [Oct4]), and genes involved in the Notch, Wnt/<i>β</i>-catenin, Hedgehog, and Hippo signaling pathways.
|
31341493 |
2019 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
All those different impacts of OCT4 on cancer indicate the biological complexity of this transcription factor in biology and, therefore, also in cancer.
|
27788386 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Also, mRNA expression of transcriptional marker Nanog and Octamer-binding transcription factor 4 (OCT4), known to enhance malignancy and metastasis in lung adenocarcinoma, was suppressed in ZNF746 siRNA-transfected H460 NSCLC cells.
|
24145959 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Although Oct-3/4 expression has been implicated in the malignancy and prognosis of glioblastomas, little is known of its involvement in drug resistances of glioblastoma.
|
25644290 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Although differentially displayed, the expression of genes related to cancer (BCL-2, p53, NF-κB, TGF-β, VEGF) and transcription and pluripotency (OCT4, NANOG, STAT3, REX1) were commonly observed in MSCs and cancer cells.
|
21638208 |
2011 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
|
20696700 |
2010 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Among astrocytomas, mRNA expression of OCT4, MYC and (less robust) KLF4 increased with malignancy, while in recurrent glioblastomas MYC expression slightly decreased.
|
27600094 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Analysis of SOX2, OCT4 and MSI1 expression revealed that inhibition of the dominant p110 subunit increased expression of cancer stem cell genes, while pan-PI3K/mTOR inhibition caused a similar, though not identical, increase in cancer stem cell gene expression.
|
27176780 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Bmi-1, CD133, Nanog and Oct-4 have been reported as cancer stem cell (CSC) markers in head and neck squamous cell carcinoma (HNSCC).
|
28220856 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification |
BEFREE |
BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
|
28645561 |
2017 |